Characterizing abdominal pain in IBS: Guidance for study inclusion criteria, outcome measurement and clinical practice

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 9, 2010, Pages 1192-1202

  Spiegel, B M R ^a,b,c,d   Bolus, R ^b,c,d   Harris, L A ^e   Lucak, S ^f   Chey, W D ^g   Sayuk, G ^h   Esrailian, E ^b,d   Lembo, A ⁱ   Karsan, H ^j   Tillisch, K ^b,c   Talley, J ^a,d   Chang, L ^b,c,d  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MAYO CLINIC   (United States)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^h WASHINGTON UNIVERSITY   (United States)

ⁱ BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^j Atlanta Gastroenterology Associates   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; ENTERITIS; FEMALE; GENERALIZED ANXIETY DISORDER; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PREDICTIVE VALIDITY; PRIORITY JOURNAL;

ABDOMINAL PAIN; ADULT; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PAIN MEASUREMENT; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 78249238722     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04443.x     Document Type: Article

References (34)

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
2. Whitehead WE, Crowell MD, Bosmajian L, et al. Existence of irritable bowel syndrome supported by factor analysis of symptoms in two community samples. Gastroenterology 1990; 98: 336-40.
3. Taub E, Cuevas JL, Cook EW III, Crowell M, Whitehead WE. Irritable bowel syndrome defined by factor analysis. Gender and race comparisons. Dig Dis Sci 1995; 40: 2647-55.
4. Spiegel B, Strickland A, Naliboff BD, Mayer EA, Chang L. Predictors of patient-assessed illness severity in irritable bowel syndrome. Am J Gastroenterol 2008; 103: 2536-43.
5. Spiegel BM, Gralnek IM, Bolus R, et al. Clinical determinants of health-related quality of life in patients with irritable bowel syndrome. Arch Intern Med 2004; 164: 1773-80.
6. Lembo A, Ameen VZ, Drossman DA. Irritable bowel syndrome: toward an understanding of severity. Clin Gastroenterol Hepatol 2005; 3: 717-25.
7. Spiegel B, Bolus R, Harris LA, et al. Measuring IBS patient reported outcomes with an abdominal pain numeric rating scale: results from the proof cohort. Aliment Pharmacol Ther 2009; 30: 1159-70.
8. Melzack R. The short-form McGill Pain Questionnaire. Pain 1987; 30: 191-7.
9. Jensen MP, McFarland CA. Increasing the reliability and validity of pain intensity measurement in chronic pain patients. Pain 1993; 55: 195-203.
10. Lembo T, Naliboff B, Munakata J, et al. Symptoms and visceral perception in patients with pain-predominant irritable bowel syndrome. Am J Gastroenterol 1999; 94: 1320-6.
11. Spiegel BMRHL, Lucak S, Mayer E, et al. Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF cohort. Am J Gastroenterol 2009; 104: 1984-91.
12. Hellstrom PM, Hein J, Bytzer P, Bjornsson E, Kristensen J, Schambye H. Clinical trial: the GLP-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomised, placebo-controlled, doubleblind study. Aliment Pharmacol Ther 2009; 29: 198-206.
13. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001; 94: 149-58.
14. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005; 113: 9-19.
15. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997; 11: 395-402.
16. Drossman DA, Li Z, Toner BB, et al. Functional bowel disorders. A multicenter comparison of health status and development of illness severity index. Dig Dis Sci 1995; 40: 986-95.
17. Spiegel BBR, Talley J, Chang L. Patient Willingness to Use ROSE-010: A Subcutaneous (SC) GLP-1 Analogue for IBS Pain Episodes. Digestive Disease Week. Volume Abstract S1316, New Orleans, LA, 2010.
18. Chang LSY, Bytzer P, TAck J, Mueller- Lissner S, Schambye H, Hellstrom PM. Impact of pain attacks on behavior and health-related outcomes in patients with irritable bowel syndrome meeting Rome III criteria. Gastroenterology 2010; 138: S111-2.
19. Hellström PMSY, Bytzer P, Tack J, Mueller- Lissner S, Schambye H, Chang L. Characteristics of acute pain attacks in patients with irritable bowel syndrome (IBS) meeting Rome III criteria. Gastroenterology 2010; 138: S-100.
20. Trentacosti AHR, Burke L, Griebel D, Kennedy D. Evolution of clinical trials for irritable bowel syndrome: issues in endpoints and study design. Am J Gastroenterol 2010; 105: 731-5.
21. Spiegel BMRN, Mayer E, Bolus R, Chang L. Development and initial validation of a concise point-of-care IBS severity index: the 4-item ''BEST'' questionnaire. Gastroenterology 2006; 130: S1040.
22. Patrick DLDD, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998; 43: 400-11.
23. Lackner JMGG, Zack MM, Katz LA, et al. Measuring health-related quality of life in patients with irritable bowel syndrome: can less be more? Psychosom Med 2006; 68: 312-20.
24. Reilly MCBA, Ricci JF, Santoro J, Stevens T. The validity and accuracy of the Work Productivity and Activity Impairment questionnaire - irritable bowel syndrome version (WPAI:IBS). Aliment Pharmacol Ther 2004; 20: 459-67.
25. Labus JS, Bolus R, Chang L, et al. The Visceral Sensitivity Index: development and validation of a gastrointestinal symptom-specific anxiety scale. Aliment Pharmacol Ther 2004; 20: 89-97.
26. Labus JS, Mayer EA, Chang L, Bolus R, Naliboff BD. The central role of gastrointestinal- specific anxiety in irritable bowel syndrome: further validation of the visceral sensitivity index. Psychosom Med 2007; 69: 89-98.
27. Kruis W, Thieme C, Weinzierl M, Schussler P, Holl J, Paulus W. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology 1984; 87: 1-7.
28. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J 1978; 2: 653-4.
29. Drossman DA, Thompson WG, Talley NJ. Identification of sub-groups of functional gastrointestinal disorders. Gastroenterology Intl 1990; 3: 159-72.
30. Revicki DA, Chen WH, Harnam N, Cook KF, Amtmann D, Callahan LF, Jensen MP, Keefe FJ. Development and psychometric analysis of the PROMIS pain behavior item bank. Pain 2009; 146: 158-69.
31. Chang L, Drossman DA. Rome Foundation Endpoints and Outcomes Conference 2009: optimizing clinical trials in FGID. Am J Gastroenterol 2010; 105: 722-30.
32. Drossman DA, Chang L, Schneck S, Blackman C, Norton WF, Norton NJ. A focus group assessment of patient perspectives on irritable bowel syndrome and illness severity. Dig Dis Sci 2009; 54: 1532-41.
33. Naliboff BD, Waters AM, Labus JS, et al. Increased acoustic startle responses in IBS patients during abdominal and nonabdominal threat. Psychosom Med 2008; 70: 920-7.
34. Irvine EJ. Review article: patients' fears and unmet needs in inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20(Suppl. 4): 54-9.